

## NEW NON-EXECUTIVE DIRECTOR – ILONA MEYER

*Highly experienced general counsel with global healthcare and technology experience*

**Adelaide, Australia, 4<sup>th</sup> March 2022:** Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for health and security markets globally, is pleased to announce the appointment of Ms Ilona Meyer to its Board as a Non-Executive Director from 7<sup>th</sup> March 2022.

Ms Meyer brings a wealth of over 20 years' experience as a senior executive in healthcare, agriculture and emerging technologies focusing on innovation and growth. Throughout her professional career across Australia and Asia, Ms Meyer has held multiple executive roles with private and public companies, including ASX-listed companies and dynamic high-growth start-ups, where she gained extensive experience in leading business transformation initiatives, managing complex stakeholders, influencing industry bodies, as well as navigating complex transactions and regulatory disputes.

Ms Meyer was a senior member of the ResMed Limited (ASX: RMD) operational leadership team from 2010 to 2016 in her role as Vice President and General Counsel (Asia Pacific). That period saw a great expansion for ResMed as it pioneered increased awareness of the sleep disorder breathing market, expanded its global network of distributors and direct sales force and changed its marketing approach based on consumer preferences and local reimbursement policies. An expansion of its manufacturing capabilities in Sydney, Singapore and Paris saw its revenues almost double to over US\$1.8B. Ms Meyer contributed to each of these business initiatives, particularly with a focus on growth within the Asia Pacific markets. Her experience included expanding ResMed's geographic presence into China, the resolution of a field safety notification throughout Asia and implementation of a dual-sourcing supplier strategy for its manufacturing operations.

Ms Meyer's diverse experience in leading and managing high performance teams has enabled the delivery of accretive acquisitions and integrations in Australia, China, New Zealand and Singapore, supported go-to-market strategies and maximised global manufacturing and supplier efficiencies, all contributing to successful international growth and expansion.

Ms Meyer will also become a member of the Micro-X Audit & Risk Committee where her extensive legal and compliance skills and highly relevant domestic and international industry experience will be valuable to Micro-X as the business continues to expand in multiple markets with new products.

Currently, Ms Meyer is the General Counsel and Head of Legal & Compliance of the Boehringer Ingelheim Group for the Australian and New Zealand division. Ms Meyer's role manages organisational risk and ensures compliance whilst delivering on the company's objective of transforming lives of patients in areas of significant unmet medical need. Ms Meyer is also the Chair and Co-Chair of their ANZ Compliance and Crisis Management Committees, respectively.

Prior to Boehringer Ingelheim, Ms Meyer was employed as General Counsel and Group Company Secretary to ASX-listed Ruralco Holdings Limited which included responsibility for all legal and compliance functions including all board committees, as well as capital raising transactions and multiple acquisitions. She was also previously General Counsel to Medtronic, Inc. (ANZ) (NYSE:MDT) and Legal Counsel, Asia Pacific to 3M Australia (NYSE:MMM).

Ms Meyer is a qualified lawyer, holding both a Bachelor and Master of Laws from the Queensland University of Technology, and is also a graduate of the Australian Institute of Company Directors (GAICD).

Micro-X's Chairman, David Knox, commented:

*"I'm both excited and thrilled to welcome Ilona to the Micro-X Board and at her joining our Audit & Risk Committee as she brings a wealth of legal, regulatory and business experience to the Company. Aside from her legal expertise, Ilona is also well-versed in M&A, in high growth and start-up companies and in strategic management as well as industrial manufacturing operations. She will undoubtedly hit the ground running, bringing fresh eyes and insights to Micro-X as we expand into European and American markets."*

This ASX Announcement is authorised by the Board of Micro-X.

– ENDS –

## About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight, and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military, and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: [www.micro-x.com](http://www.micro-x.com)

## CONTACTS

Micro-X Limited	Investor Enquiries
<b>Peter Rowland</b> , Managing Director <b>Kingsley Hall</b> , CFO & Company Secretary  Tel: +61 8 7099 3966 E: <a href="mailto:admin@micro-x.com">admin@micro-x.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 E: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a> <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>